KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $3.3 million.

  • Castle Biosciences' Net Cash Flow fell 6460.0% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.4 million, marking a year-over-year decrease of 35168.63%. This contributed to the annual value of $20.9 million for FY2024, which is 18656.41% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Net Cash Flow is $3.3 million, which was down 6460.0% from -$7.5 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Net Cash Flow ranged from a high of $24.8 million in Q4 2024 and a low of -$139.0 million during Q3 2022
  • Over the past 5 years, Castle Biosciences' median Net Cash Flow value was -$8.1 million (recorded in 2023), while the average stood at -$17.1 million.
  • Per our database at Business Quant, Castle Biosciences' Net Cash Flow crashed by 259248.35% in 2022 and then skyrocketed by 30182.76% in 2024.
  • Over the past 5 years, Castle Biosciences' Net Cash Flow (Quarter) stood at -$33.5 million in 2021, then soared by 66.52% to -$11.2 million in 2022, then skyrocketed by 167.82% to $7.6 million in 2023, then soared by 224.89% to $24.8 million in 2024, then crashed by 86.57% to $3.3 million in 2025.
  • Its Net Cash Flow stands at $3.3 million for Q3 2025, versus -$7.5 million for Q2 2025 and -$30.0 million for Q1 2025.